Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Key findings from multisite implementation of electronic health record tools for clinical pretest probability of pulmonary embolism in the emergency department
Houghton, Damon E. , Keenan, Megan , Dykhoff, Hayley J. , Campbell, Kyle N., Hall, Marie Boas, Heaton, Heather A. , Thompson, Kristine M., Aranda, Jamie, Balgord, Sarah , Rubin, Jonathan M. , Hanson, Ryan , He, Wei , Cahill, Emily , Heaton, Heather, Thompson, Kristine, Houghton, Damon E , Hall, Marie, Raja, Ali S , Dutta, Sayon , McEvoy, Dustin , Kreuziger, Lisa Baumann , Rosovsky, Rachel

Mayo Clinic

Vascular Medicine | June 16, 2025 | Volume: 30 | Issue: 3 | Pages: 302-308

10.1177/1358863x251337456 | PMID 40521851 Get It

Background: The use of validated risk stratification tools for the workup of suspected pulmonary embolism (PE) is a recommendation of the American Society of Hematology and the American College of Emergency Physicians. Methods: We designed and implemented electronic clinical pretest probability (PTP) tools for use in emergency departments (ED). Overall, 38 EDs (tertiary and regional EDs) in the United States were involved across three health systems. PTP use was analyzed between September 12, 2022 and January 11, 2023 in 270,247 ED visits. PTP use was examined in terms of the percentage of visits for which patients underwent computed tomography pulmonary angiography (CTPA). Each site chose the 3-tier Wells’ score for implementation and Site 2 designed a combined Wells’, pulmonary embolism rule-out criteria (PERC), and YEARS score. Results: At Site 3, forced use resulted in documented PTP scores in 49–53% of ordered CTPAs. At Sites 1 and 2, where PTP scores were optional, documented PTP scores occurred in 2–3% and 1–3% of CTPA orders, respectively. At Site 1, the use of PTP increased slightly over the study period, with signs that PE yield on imaging was also increasing (3.4–5.9%). At Site 2, PE yield on imaging was 9–10%, and it remained similar, with similar use of PTP tools over the study period. PE yield (6–8%) on imaging also remained similar throughout the study at Site 3. Conclusions: Guideline-endorsed PTP scores for PE at three independent health systems in the United States did not increase PE yield on imaging. Novel implementation strategies involving interdisciplinary teams are urgently needed.
Measuring artery diameter in rabbit angiograms for neurovascular disease modeling applications and device testing
Khan, YM , Franklin, J Ford, Bayraktar, Esref Alperen , Oliver, Alexander A , Ding, Yonghong , Lortscher, Sarah, Brinjikji, Waleed , Kadirvel, Ramanathan , Kallmes, David F. , Khan, Yasmine , Franklin, Jack , Bayraktar, Esref Alperen , Oliver, Alexander A , Ding, Yong-Hong , Lortscher, Sarah , Brinjikji, Waleed , Kadirvel, Ram , Kallmes, David F , Cortese, Jonathan

Mayo Clinic

Interventional Neuroradiology | June 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199251347398 | PMID 40491341 Get It

Background and purpose New Zealand White Rabbits are a useful preclinical model for neurovascular research. Inducing right common carotid artery aneurysms in New Zealand White Rabbits gives researchers the ability to test neurovascular devices in vivo. This study takes advantage of archived angiograms to obtain vascular measurements of interest for future research in rabbit models. Methods Rabbit angiograms from endovascular studies conducted in-house between 2005 and 2024 were analyzed using ImageJ at points of interest along the thoracic and abdominal aorta. Using scale references, the diameters of various New Zealand White Rabbit (2.5–3.5 kg) arteries were measured for aneurysm models and controls. Anatomic vascular variations were categorized and recorded. Results Measurable artery diameters at 39 points of interest were recorded for 170 female New Zealand White Rabbits. Type 1 vascular anatomy was the most common rabbit aortic arch, characterizing 85% of identifiable rabbit anatomies in this study. Conclusion By making these measurements available, this study simplifies future neurovascular studies, allowing for vasculature to be selected by size depending on the application. Additionally, the study offers insight into the relationship between elastase-induced aneurysms and surrounding vasculature size and draws size comparisons between some key arteries of interest.
The Impact of Social Determinants of Health on the Severity of Symptoms at Presentation and Discharge Disposition in Patients Undergoing Surgical Treatment of Cervical Myelopathy
Francois, Hendrick , Boateng, Atta , Jiang, Kelly , Johnson, Sarah E. , Smith, Kitara, Azad, Tej D., Ashayeri, Kimberly , Johnson, Sarah, Theodore, Nicholas , Weber-Levine, Carly , Mahapatra, Smruti , Davidar, A. Daniel , Hersh, Andrew M. , Alomari, Safwan , Bhimreddy, Meghana , Azad, Tej Deepak , Theodore, Nicholas

Mayo Clinic

Neurosurgery | June 9, 2025 | Volume: 98 | Issue: 1 | Pages: 211-220

10.1227/neu.0000000000003557 | PMID 40488526 Get It

BACKGROUND AND OBJECTIVES: Social determinants of health (SDOH), such as education, insurance, race, and income, significantly affect a patient's medical care and surgical outcomes. Additional studies characterizing the impact of SDOH on patients undergoing spine surgery are needed. Accordingly, this study evaluates the impact of SDOH on severity of symptoms at presentation and discharge disposition in patients undergoing surgical treatment of cervical myelopathy. METHODS: A retrospective single-center study identified adult patients undergoing surgical intervention for cervical myelopathy between 2016 and 2020. Cohort characteristics were collected from patient medical records. The t -test, Wilcoxon rank-sum, analysis of variance, Kruskal-Wallis, and χ 2 tests were used to compare variables when appropriate. Multivariable linear and logistic regression analyses were conducted for modified Japanese Orthopaedic Association (mJOA) and discharge disposition. All statistical analysis was performed in MATLAB R2022b (MathWorks, Natick, MA). RESULTS: A total of 480 patients were included in the study with a male predominance of n = 281 (59%) and a mean age of 62 ± 13 years. Racial demographics included 64% White (n = 308) and 36% Non-White (n = 172) patients. On univariable analysis, mJOA at presentation was significantly associated with employment status ( P < .01), annual income ( P < .01), education level ( P < .01), and insurance status ( P = .03). On multivariable analysis, annual income and education level continued to be significant predictors of presenting mJOA. On univariable analysis, discharge disposition was associated with body mass index ( P = .01), mJOA at presentation ( P < .01), employment status ( P = .05), annual income ( P < .01), education level ( P < .01), insurance ( P < .01), approach ( P < .01), and length of stay ( P < .01). On multivariable analysis, mJOA at presentation, education level, insurance, and approach continued to be significant predictors of discharge disposition. CONCLUSION: SDOH affect the severity of symptoms at presentation and discharge disposition in patients undergoing surgery for cervical myelopathy. Understanding these dynamics and uncovering additional SDOH are critical for enhancing surgical care and achieving equitable healthcare outcomes.
Rebuilding the Tower of Babel: The Current Landscape and Emerging Opportunities in DEE-SWAS
Stowe, Robert C. , Kelley, Sarah A. , Bhatia, Sonal , McLaren, John R. , Rao, Lekha M. , Patel, Shital H., Fine, Anthony L. , Baumer, Fiona M. , Duong, Priscilla, Pavuluri, Spriha , Liu, Virginia B., Phillips, Donald J. , Fine, Anthony , Baumer, Fiona M , McLaren, John R., Phillips, Donald J.

Mayo Clinic

Epilepsy Currents | June 9, 2025 | Volume: 25 | Issue: 6 | Pages: 369-377

10.1177/15357597251344191 | PMID 40502808 Get It

Developmental/epileptic encephalopathy with spike-wave activation in sleep (DEE-SWAS) is newly proposed nomenclature put forth by the International League Against Epilepsy (ILAE) to replace the problematic electrographic and/or clinical phenotypes of electrical status epilepticus of sleep (ESES) and continuous spike-wave in sleep (CSWS). The nomenclature update represents a noble effort to minimize the confusion of how to define and appropriately utilize this alphabet soup of acronyms, thereby aiding in future clinical and research efforts. The name change fails to capture greater challenges within the field, which still plague diagnosis and treatment and stagnates substantive research advancements. Through a directed literature review of DEE-SWAS with emphasis on the new ILAE nomenclature and the RESCUE-ESES trial, we will highlight major persistent quandaries in the field. These include inadequate or insufficient diagnostic biomarkers (ie, the spike wave index), the highly variable clinical manifestations, ranging from dubious associations to profound developmental regression, presumptively caused by spike-wave activation in sleep, and variable and often ineffective treatment paradigms. We will also review the broader diagnostic evaluation of DEE-SWAS. By doing so, we aim to shed light on crucial research and clinical questions that could advance our understanding of diagnosing and treating children with DEE-SWAS, as well as addressing the uncertainty surrounding the neurological effects of sleep-activated epileptiform discharges.
The longevity effects of reduced IGF-1 signaling depend on the stability of the mitochondrial genome
Shemtov, Sarah J. , McGann, Eric, Carrillo, Lucy , Lee, Sang‐Min , Anson, Herbert, Chung, Claire S, Anagnostou, Maria‐Eleni, Lai, Guan-Ju, Wan, Junxiang , Vorobyova, Ivetta, Conover, Cheryl A. , Cohen, Pinchas , Kennedy, Scott R. , Goût, Jean-François , Haroon, Suraiya , Vermulst, Marc , Sanchez-Contreras, Monica , Conover, Cheryl A , Thorwald, Max A , Cohen, Pinchas , Kennedy, Scott R , Gout, Jean-François , Haroon, Suraiya , Lee, Sangmin , Hwang, Eric , Verheijen, Bert M. , Sanchez-Contreras, Monica, Thorwald, Max A.

Mayo Clinic

No container title available | June 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.06.03.656903 | PMID 40501628 Get It

ABSTRACT Suppression of insulin-like growth factor-1 (IGF-1) signaling extends mammalian lifespan and protects against a range of age-related diseases. Surprisingly though, we found that reduced IGF-1 signaling fails to extend the lifespan of mitochondrial mutator mice. Accordingly, most of the longevity pathways that are normally initiated by IGF-1 suppression were either blocked or blunted in the mutator mice. These observations suggest that the pro-longevity effects of IGF-1 suppression critically depend on the integrity of the mitochondrial genome and that mitochondrial mutations may impose a hard limit on mammalian lifespan. Together, these findings deepen our understanding of the interactions between the hallmarks of aging and underscore the need for interventions that preserve the integrity of the mitochondrial genome.
Collapse of interictal suppressive networks permits seizure spread
Makhoul, Ghassan S. , Doss, Derek J. , Withers, C Price , Cavender, Addison C. , Lerma, Bruno Hidalgo Monroy , Reda, Anas, Bibro, Camden E. , Liao, Emily, Dawant, Benoît M. , Reddy, Shilpa B. , Crudele, Angela, Bick, Sarah K. , Morgan, Victoria L. , Englot, Dario J. , Constantinidis, Christos , Williams Roberson, Shawniqua , Englot, Dario J , Doss, Derek J , Morgan, Victoria L , Bick, Sarah K , Johnson, Graham W. , Kang, Hakmook , Reddy, Shilpa B.

Mayo Clinic

Brain | June 5, 2025 | Volume: 148 | Issue: 12 | Pages: 4275-4287

10.1093/brain/awaf215 | PMID 40473247 Get It

Abstract How do brain networks limit seizure activity? In the interictal suppression hypothesis, we recently postulated that high inward connectivity to seizure onset zones (SOZs) from non-involved zones (NIZs) is a sign of broader network suppression. If broad networks appear to be responsible for interictal SOZ suppression, what changes during seizure initiation, spread and termination? For patients with drug-resistant epilepsy, intracranial monitoring offers a view into the electrographic networks that organize around and in response to the SOZ. In this manuscript, we investigate network dynamics in the peri-ictal periods to assess possible mechanisms of seizure suppression and the consequences of this suppression being overwhelmed. Peri-ictal network dynamics were derived from stereo electroencephalography recordings from 75 patients with drug-resistant epilepsy undergoing presurgical evaluation at Vanderbilt University Medical Center. We computed directed connectivity from 5 s windows in the periods between, immediately before, during and after 668 seizures. We aligned connectivity matrices across seizures and patients, then calculated net connectivity changes from the SOZ, propagative zone and NIZ. Across all seizure types, we observed two phases: a rapid increase in directed communication towards the SOZ, followed by a collapse in network connectivity. During the first phase, SOZs could be distinguished from all other regions (one-way ANOVA, P = 8.32 × 10−19–2.22 × 10−7). In the second phase and post-ictal period, SOZ inward connectivity decreased yet remained distinct (one-way ANOVA, P = 2.58 × 10−10–1.66 × 10−2). NIZs appeared to drive increased SOZ connectivity while intra-NIZ connectivity decreased concordantly. Stratifying by seizure subtype, we found that consciousness-impairing seizures decrease inward connectivity from the NIZ earlier than consciousness-sparing seizures (one-way ANOVA, P &lt; 0.01 after false discovery correction). Tracking network reorganization against a surrogate for seizure involvement highlighted a possible antagonism between seizure propagation and the ability of the NIZ to maintain high connectivity to the SOZ. Finally, we found that inclusion of peri-ictal connectivity improved the accuracy of SOZ classification from previous models to a combined area under the curve of 93%. Overall, NIZs appear actively to increase inhibitory signaling towards the SOZ during seizure onset, possibly to thwart seizure activity. Although inhibition appears insufficient to prevent seizure onset, the inability to restrict seizure propagation might contribute to loss of consciousness during larger seizures. Dynamic connectivity patterns uncovered in this work might: (i) facilitate accurate delineation of surgical targets in focal epilepsy; (ii) reveal why interictal suppression of SOZs might be insufficient to prevent all seizures; and (iii) provide insight into mechanisms of loss of consciousness during certain seizures.
Behavioral Feedback During Cochlear Implant Array Insertion Under Local Anesthesia: A New Frontier in Cochlear Implant Care and Research
Khandalavala, Karl R. , Wu, Pei‐zhe , Etler, Christine P. , Hansen, Marlan R. , Marinelli, John P. , Ostlie, Sarah E., Lohse, Christine M. , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | June 4, 2025 | Volume: 46 | Issue: 8 | Pages: 933-937

10.1097/mao.0000000000004548 | PMID 40467117 Get It

Objective To describe the potential applications of awake cochlear implantation (CI). Patients Adult patients with sensorineural hearing loss who qualify for CI. Interventions CI under local anesthesia, without any form of systemic analgesia or anesthesia. Main Outcome Measures Acoustic hearing preservation, subjective patient report of cochlear implant pitch matching, and subjective patient report of cochlear implant sound quality. Results Four illustrative cases are presented, highlighting the potential uses of CI performed under local anesthesia for optimizing outcomes in hearing preservation, implant pitch matching, and implant sound quality. Conclusions CI under local anesthesia allows surgeons to use real-time patient feedback during electrode array insertion to minimize intracochlear trauma, particularly in cases where hearing preservation is a goal of CI, and to potentially improve implant performance by optimizing pitch matching and sound quality.
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Jagannath, Sundar , Martin, Thomas G. , Lin, Yi , Cohen, Adam D. , Raje, Noopur , Htut, Myo, Deol, Abhinav , Agha, Mounzer , Berdeja, Jesús G. , Liegel, Jessica J., Dhakal, Binod , Parekh, Samir , de, Rocío Montes , Plaks, Vicki , Sun, Huabin, Banerjee, Arnob , Schecter, Jordan M. , Lendvai, Nikoletta , Lengil, Tamar, Zhu, Jieqing, Koneru, Mythili, Akram, Muhammad, Patel, Nitin , Filho, Octavio Costa, Voorhees, Peter M. , Liegel, Jessica J , Rossi, Adriana , Lieberman-Cribbin, Alex , Usmani, Saad , Dhakal, Binod , Parekh, Samir , Montes de Oca, Rocio , Jakubowiak, Andrzej , Voorhees, Peter , Cohen, Adam D , Jagannath, Sundar , Lin, Yi , Berdeja, Jesús G , Raje, Noopur S , Htut, Myo , Lesokhin, Alexander M. , Rossi, Adriana , Usmani, Saad Z. , Li, Hui, Wang, Rui , Madduri, Deepu , Jakubowiak, Andrzej

Mayo Clinic

Journal of Clinical Oncology | June 3, 2025 | Volume: 43 | Issue: 25 | Pages: 2766-2771

10.1200/jco-25-00760 | PMID 40459151 Get It

CARTITUDE-1 evaluated ciltacabtagene autoleucel (cilta-cel) in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM). We describe overall survival (OS), ≥5-year progression-free outcomes, associated biomarkers, and safety, with a median study follow-up of 61.3 months. For the 97 treated patients, median OS was 60.7 months (95% CI, 41.9 to not estimable). One third (32/97) of patients remain alive and progression-free for ≥5 years after a single cilta-cel infusion, without maintenance treatment. Twelve of these patients treated at a single center underwent serial minimal residual disease (MRD) and positron emission tomography-computed tomography assessments, and all (100%) were MRD-negative (at least 10 −5 threshold) and imaging-negative at year 5 or later after cilta-cel. Baseline characteristics, including the presence of high-risk cytogenetics and extramedullary disease, were generally comparable for the 32 patients who were progression-free for ≥5 years versus patients who had progressive disease by year 5. A trend of lower baseline tumor burden, higher fraction of naïve T-cells in the cilta-cel drug product, higher T cell-to-neutrophil ratio, higher hemoglobin and platelets at baseline, and higher effector-to-target ratio were associated with ≥5-year progression-free status. The safety profile of cilta-cel remained consistent with previous reports. To our knowledge, our data provide the first evidence that cilta-cel is potentially curative in patients with RRMM.
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
Babiker, Hani M. , Picozzi, Vincent J. , Chandana, Sreenivasa R , Melichar, Bohuslav, Kasi, Anup , Gang, Jin, Gállego, Javier , Bullock, Andrea J. , Chunyi, Hao, Hitre, Erika, Osipov, Arsen , Alés, Inmaculada, Dragovich, Tomislav, Lee, Woo Jin , Feeney, Kynan, Ueno, Makoto , Seufferlein, Thomas , Investigators, on behalf of the PANOVA-3 Study, Osipov, Arsen, Matrana, Marc , Blondin, Nicholas, Shroff, Rachna T. , Orr, Douglas, Anderson, Michael J. , Shields, Anthony F. , Hamm, John , Bullock, Andrea, Nagireddy, Sumana, Kolodney, Joanna, Dragovich, Tomislav, Maniam, Ajit, Sears, Judith D., Stilwill, Joseph, Cusnir, Mike , Niewiaroska, Anna, Small, William, Kasi, Anup, Tache, Jason, Ross, Sharona, Shihabi, Samer, Gandhi, Sunil, Reeves, J. N. , Green, Garrett , Feinstein, Trevor, Huyck, Timothy K., Ramdin, Nadia, Marsh, Robert , Jiang, Yixing , Hatoum, Hassan , Manda, Sudhir, Kochenderfer, Mark D., Illum, Henrik, Richards, Donald , Valilis, P., Wong, Lucas, Newton, Herbert B. , Abdelrahim, Maen, Einspahr, David, Siegel, Richard, McKenney, Scott, Narang, Mohit , Cárdenes, Higinia R. , Thanikachalam, Kannan , Raff, Joshua P. , Ye, Joseph , Behl, Deepti , Kam, Audrey E., DeRose, Paul, Tasneem, A. , Brenner, Warren, Santos, Jennifer De Los , Rausch, D C, Trikha, Gaurav, Gabrail, Nashat , Mowat, Rex B., Jahangir, Khawaja, Schumaker, Robert P. , Soffen, Edward , Bravin, Eric, Gupta, Mukul Kumar , Bedoya-Apraez, Ivan Dario, Kang, Tyler Y., Lemay, Frédéric , Vincent, Mark , Létourneau, Richard, Doehring, Christine, Haberkorn, Mike, Rußwurm, Karen, Chater, Jack, Küng, Marc , Schacher, Sabine, Passhak, Maria , Geva, Ravit , Hubert, Ayala, Golan, Talia , Senellart, Hélène, Trouilloud, Isabelle , Blan, Jean-Frederic, Dourthe, Luis-Marie, Roy, Florence Le, Martin-Babau, J., Greil, Richard , Schreil, Georg, Gerger, Armin , Eisterer, Wolfgang , Mercadé, T. Macarulla, Cubillo, Antonio , Pons, Francesc Valladares, Díaz, Inmaculada Alés, Rivera, Fernando , Sarvise, Mariano Ponz, Airoldi, Mario , Bellotti, Giovanna, Corsi, Domenico , Antonuzzo, Lorenzo , Melichar, Bohuslav, Holečková, Petra , Kotasek, Rostislav, Němeček, Radim , Cutsem, Eric van, Laethem, Jean‐Luc Van , Sym, Sun Jin , Kim, Jin Young , Oh, Sang Cheul , Park, Joon Oh, Kim, Jin Won , Lee, Myung Ah , Choi, Hye Jin, Kang, Seok Yun , Mruk, Andrzej, Freier, Beata, Kosakowska, Ewa Anna, Kocsis, Judit, Csőszi, Tibor , Hitre, Erika, Al-Farhat, Yousuf, Cang, Shundong , Jin, Gang , Zuo, Changzeng, Song, Lijie, Wu, Zheng , Gao, Jie , Zhang, Tao� , Wang, Yusheng , Yuan, Xin , Li, Zhi-Hua , Chen, Rufu , Cai, Xiujun , Zhu, Zhizhen, Bai, Yuxian , Bai, Chunmei, Yau, Thomas, Joubert, Warren , Wong, Ka Yeung Mark, Harris, Marion , Mišir, Ana, Faccio, Adilson , Cruz, Felipe Melo , Azevedo, Srergio De, Victorino, Ana Paula , Paiva, Tadeu Ferreira, Franke, Fábio , Tiscoski, Katsuki Arima , Parolla, Gabriel, Lilno, Flora, Siqueira, Mariana Bruno , Lyra, Marcos, Lira, Jose Luis Martinez, Oliva, Dolores Mendoza, Vazquez, Arturo, Luviano, Jesus Elvis Cabrera, Gutiérrez, Erika Castillo , Camargo, Vanessa Rosas, Guerra, Cristian Chavez, Flores, Osvaldo Hernandez, Contreras, Jessica Reyes, Villanueva, Ángel Gómez, Villanueva, Omar Zayas, Bullock, Andrea , Wyrwicz, Lucjan , Osipov, Arsen , De La Fouchardiere, Christelle , Lee, Woojin , Ueno, Makoto , Van Cutsem, Eric , Macarulla, Teresa , Babiker, Hani , Antonuzzo, Lorenzo , Melichar, Bohuslav, Kasi, Anup , Gang, Jin, Gallego, Javier , Hitre, Erika, Fouchardière, Christelle de la , Dragovich, Tomislav, Philip, Philip A. , Cutsem, Eric Van , Macarulla, Teresa , Investigators, on behalf of the PANOVA-3 Study, Spigel, David R. , Osipov, Arsen, Lou, Emil , Bullock, Andrea, Dragovich, Tomislav, Coveler, Andrew L. , Arena, Francis P. , Kasi, Anup, Ross, Sharona , Reeves, James, Green, Garrett, Uemura, Marc Isamu , Ye, Joseph, Wang, James Z. , Rausch, Daniel, Park, Jae‐Hyun , Schumaker, Robert, Gupta, Mukul, Letourneau, Richard, Fuchs, Martin , Vogel, Arndt , Chater, Jack, Schacher, Sabine, Stemmer, Salomon M. , Dourthe, Luis-Marie, Abdelghani, Méher Ben , Pons, Francesc Valladares, Guillén‐Ponce, Carmen , Yayá, Ricardo , Ponz‐Sarvisé, Mariano , Vincenzi, Bruno , Melichar, Bohuslav, Petruzelka, Lubos B. , Cutsem, Eric van, Borbath, Ivan , Hwang, Jun‐Eul , Oh, Sung Yong , Lee, Moon Hee , Choi, Hye Jin , Chon, Hong Jae , Ramlau, Rodryg , Mruk, Andrzej, Hitre, Erika, Bassam, Ali, Hao, Chunyi , Liang, Bo , Li, Wei , Bai, Chunmei , Joubert, Warren, Marx, Gavin M. , Azevedo, Srergio De, Hoff, Paulo M. , Vazquez, Arturo, Guerra, Cristian Chavez, Cortez, David Orta, Campos-Gómez, Saúl , Espinoza, Iván Romarico González

Mayo Clinic

Journal of Clinical Oncology | May 31, 2025 | Volume: 43 | Issue: 21 | Pages: 2350-2360

10.1200/jco-25-00746 | PMID 40448572 Get It

PURPOSE Tumor treating fields (TTFields) use alternating electric fields to disrupt cancer cell proliferation. Feasibility of TTFields therapy with gemcitabine/nab-paclitaxel was previously demonstrated in patients with advanced pancreatic adenocarcinoma. PANOVA-3 was designed to confirm safety and efficacy of TTFields in patients with unresectable locally advanced pancreatic adenocarcinoma (LA-PAC). METHODS In this global phase III trial, 571 patients with newly diagnosed LA-PAC were randomly assigned to receive gemcitabine 1,000 mg/m 2 and nab-paclitaxel 125 mg/m 2 by intravenous infusion once a day on days 1, 8, and 15 of a 28-day cycle with or without TTFields. The primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), local PFS, pain-free survival, and overall response rate (ORR). Distant PFS was analyzed post hoc. RESULTS OS was significantly prolonged using TTFields with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel (median, 16.2 months [95% CI, 15.0 to 18.0] v 14.2 months [95% CI, 12.8 to 15.4]; hazard ratio [HR], 0.82 [95% CI, 0.68 to 0.99]; P = .039). PFS, local PFS, and ORR were not improved. Pain-free survival was significantly prolonged with TTFields with gemcitabine/nab-paclitaxel (median, 15.2 months [95% CI, 10.3 to 22.8] v 9.1 months [95% CI, 7.4 to 12.7]; HR, 0.74 [95% CI, 0.56 to 0.97]; P = .027), as was distant PFS (median, 13.9 months [95% CI, 12.2 to 16.8] v 11.5 months [95% CI, 10.4 to 12.9]; HR, 0.74 [95% CI, 0.57 to 0.96]; P = .022). Device-related skin adverse events (AEs) were experienced by 76.3% of patients. Most device-related skin AEs were mild to moderate, with 7.7% of patients reporting a grade 3 AE. CONCLUSION This study demonstrated significant OS, pain-free survival, and distant PFS benefits for TTFields with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in patients with unresectable LA-PAC, with no additive systemic toxicity.
The Role, Challenges, and Employment Characteristics of Disability Resource Professionals in Medical Education: A National Study
Broskowski, Erin , Triano, Sarah , James, Kara , Betchkal, Rylee , Echols, Karyn LaTurner , Hawks, Suzanne , Ogah, Ochanya, Nguyen, Mytien , Meeks, Lisa M. , Triano, Sarah E , James, Kara

Mayo Clinic

Journal of Medical Education and Curricular Development | May 31, 2025 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/23821205251344771 | PMID 40452895 Get It

Background Disability disclosure and accommodation requests among US medical students have increased significantly, yet gaps in support persist. Disability resource professionals (DRPs) are one essential support in bridging these gaps, but only 9% of medical schools employ a dedicated DRP, leaving institutions potentially underprepared to address the needs of students with disabilities. Objective This study explored the roles, qualifications, and challenges of DRPs in US medical schools to identify barriers to job performance and inform strategies for strengthening and supporting this role in medical education. Methods An exploratory, cross-sectional survey was conducted in July to August 2023. A 27-question online survey was distributed through convenience and snowball strategy via social media and listservs. Questions addressed institutional structures, the size of DRP student caseloads, job satisfaction, mentorship, and barriers to managing caseloads. Quantitative data were analyzed using descriptive statistics and χ 2 tests, qualitative responses were thematically analyzed. The University of Michigan IRB approved this study. Results Seventy-nine DRPs from 72 US MD and 7 DO programs participated. Most respondents reported excessive workloads, with 30% managing caseloads exceeding 100 students. Less than half of DRPs (45.6%) indicated that their workload was manageable. Inadequate professional development, lack of mentorship, and low salary satisfaction emerged as common challenges. Respondents also reported institutional barriers, including stigma, faculty resistance to accommodations, and the complexity of coordinating disability accommodations across didactic, clinical, and testing environments. Discussion DRPs are critical to fostering accessible and inclusive medical education, yet systemic barriers undermine their effectiveness and place institutions at risk of increased student attrition, legal liability, and resource strain. Addressing these challenges requires investments in manageable caseloads, professional development for DRPs, faculty training, and institutional prioritization of the DRP role. Conclusions Systemic investments in staffing, training, and institutional culture are necessary to support DRPs and the growing population of US medical students with disabilities (MSWDs).